A cloned cell line mediating natural killer cell function inhibits immunoglobulin secretion by unknown
Brief DeNnitive Report 
A  CLONED  CELL  LINE  MEDIATING 
NATURAL  KILLER  CELL  FUNCTION 
INHIBITS  IMMUNOGLOBULIN  SECRETION* 
BY GARY NABEL, W. JEFFREY ALLARD, AND HARVEY CANTOR 
From the Departments of Cell Biology and Pathology, Harvard Medical School and Sidney Farber Cancer 
Institute, Boston, Massachusetts 
We have previously shown that T  cell clones can mediate multiple biologic activities 
(1).  Inducer T  cell clones, for example, may stimulate immunoglobulin  (Ig) secretion 
~md  activate  mast  cell  and  T  cell  proliferation  (1,  2).  Similarly,  we found  (3)  that 
clones with natural  killer cell activity can also mediate antibody-dependent  cellular 
cytotoxicity. Because these clones lysed syngeneic B  lymphocytes, we considered  the 
possibility that  this cell  might be involved in the regulation of Ig secretion.  We test 
this  hypothesis  in  this  report.  We  show  that  the  antibody  responses  of T  plus  B 
lymphocytes containing <1% cloned natural  killer  (NK)  cells are severely impaired, 
and the primary cellular target of suppression is the B cell. We suggest that some NK 
cells may regulate Ig secretion through the recognition of marker molecules expressed 
on the surface of activated B lymphocytes not linked to the major histocompatibility 
complex. 
Materials  and Methods 
Animals.  Cells  for cloning were  obtained  from C57BL/6  mice.  Cells  from  C57BL/6  or 
BALB/c mice (obtained from The Jackson Laboratory, Bar Harbor, ME) were used to produce 
conditioned medium. 
Antisera.  Lyt-l.2 and Lyt-2.2 antisera, prepared as described  (4), were kindly donated by 
Dr. F. W. Shen; NK-1 antisera were donated by Dr. G. Koo; monoclonal (mc)  anti-Thy-l.2 
were donated by Dr. Ed Clark; and mc-anti-Lyt-1 and mc-anti-Lyt-2 were donated by Dr. J. 
Ledbetter and Dr. L. Herzenberg. 
Cell Culture and Cloning.  Culture conditions for initiation and maintenance of cell lines have 
been described (5). 
Frozen Cells for Storage.  Cloned cells  were frozen in liquid  N2 and  thawed with complete 
reeovery of growth  and  function,  using  a  modification  (5)  of the  method  of Lionetti  and 
colleagues (6). 
Assays of Biologic Function.  Lysis of the YAC-1 lymphoma, an NK-sensitive tumor (7, 8), was 
used  to  define  NK  activity,  as  previously described  (3). Preparation  of selected  lymphoid 
populations (1), lipopolysaccharide (LPS)-activated B cells (3), and stimulation and enumera- 
tion of plaque-forming cells (PFC) (9) are detailed elsewhere. 
Cellular Reconstitution oflrradiated  Adoptive Hosts.  Highly purified B cells  (106), prepared  as 
above,  were  injected  into  a  lateral  tail  vein  of irradiated  (700  rad)  recipients  with  10  /.tg 
trinitrophenyl  (TNP)-Ficoll  (TNP:FicolI--24:l).  Increasing  numbers  of  Ly-I-2-NK-I+/11 
clones (C1.) were injected separately into a second lateral tail vein. PFC responses were tested 
5 days later using TNP-coupled sheep erythrocytes (SRBC) as indicator cells  (9). Each group 
represents the mean of three to five mice. 
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To test T  cell function in vivo,  l0  s T  cells were enriched as previously described  (3)  and 
injected separately from CI.Ly-I-2-NK-I+/ll as above. Spleen cells were removed 7 d later 
and incubated with purified B cells and SRBC in vitro. Anti-SRBC PFC were enumerated 4 
d  later.  Each  group  represents the  mean  of three  individual  cultures.  In no case  was  the 
standard error of the mean > 15%. 
Results 
CI.Ly-I-2-NK-I+/ l l Lyses Activated B Lymphocytes.  We previously analyzed cellular 
targets of cloned NK-like cells. Susceptible targets include LPS-activated B lympho- 
cytes, but  concanavalin  A  (Con  A)-activated T  cells,  thymocytes, fetal  liver,  bone 
marrow cells or mast cell clones are relatively resistant to lysis (Fig.  1). 
CI.Ly-I-2-NK-I+/ll  Inhibits  Ig  Secretion In  Vitro.  Because  lysis  of B  cell  targets 
occurs  very efficiently, with  effector-to-target ratios  as  low  as  1:10,  we  tested  the 
ability of NK-1+/11 cells to inhibit Ig secretion by B cells. Addition of small numbers 
of NK-I+/ll  cells  to  spleen  cells  caused  potent  inhibition  of Ig  secretion.  This 
suppression was nonspecific, inhibiting  primary responses both to sheep or chicken 
erythrocytes  (Table  I A)  or  total  Ig  secretion  (data  not  shown).  Suppression  was 
observed when cloned cells constituted  as few as 0.2% of total cells in culture.  Cell- 
free  supernatant  from  this  clone  did  not  reduce  Ig secretion,  suggesting  that  this 
inhibition was mediated directly by cells. Because NK-1 +/11  does not lyse or phago- 
cytize erythrocytes, spleen cells rather than antigen appeared to be the likely targets 
of suppression. In addition,  because the doubling time of NK-I+/11 was ~24 h, this 
suppression was probably not caused by crowding in cell cultures. Other T  cell clones 
with  similar  growth  rates  do  not  inhibit  Ig  secretion  (5).  To  test  whether  this 
suppression might result from direct action on B lymphocytes, T  cell-replacing factor 
(10)  was added to cultures containing either B lymphocytes or B cells and increasing 
numbers of NK-I+/11 cells. As few as 5 ×  103 NK-I+/11 cells inhibited Ig secretion 
by 106 B cells (Table I B). 
CI.Ly-I-2-NK-I+/ll  Inhibits  Ig  Secretion In  Vivo.  To  determine  whether  CI.Ly- 
1-2-NK-1+/11  cells could  mediate suppression  under physiologic conditions,  these 
ceils were injected by vein into irradiated recipient mice reconstituted with selected 
lymphocyte populations.  Increasing numbers of NK-I+/11 cells were injected  sepa- 
rately into a different tail vein from test lymphocytes to eliminate the possibility of an 
in  vitro interaction.  Irradiated recipients were infused  with  106  B  cells,  challenged 
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Fro.  1.  Cellular targets of Ci.Ly-I-2-NK-I+/ll. C1.Ly-I-2-NK-I+/ll incubated with radiola- 
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TASLE  I 
Inhibition of Ig Secretion by CL L  y- I- 2-NK- I+  / I l 
Number of  Final concen- 
Cloned cells 
Ly-I cells per  per culture  tration ofT  Anti-SRBC Ig  Anti-CP,.BC Ig 
culture  cell-replacing  PFC/culture  PFC/cuhure 
(X l0  s)  (X 104)  factor/culture 
0  0  190+21  190±6 
2  0  2,000 ±  345  840 ±  43 
2  1  250 ±  29  33 ±  4 
2  0.2  550 +  22  550 ±  22 
0  0  0  34 "+- 4  ND 
0  0  10  668 _+ 52  ND 
0  5  10  40 ±  5  ND 
0  1  10  180 ±  85  ND 
0  0.5  10  312 ±  40  ND 
(A) CI.Ly-I-2-NK-I+/ll  cells were added to mixtures of Ly-1 cells from B6 mice immune to sheep or 
chicken  erythrocytes  (CRBC),  10  °  nonimmune  B6  B  ceils,  and  l0  s  erythrocytes.  Cell  cultures  were 
incubated  for 4  d  before anti-SRBC  or CRBC  PFC  were enumerated, as described  in  Materials and 
Methods. (B) CI.Ly-I-2-NK-I*/I 1 cells were added to 10  6 B cells, l0  s erythrocytes, and T  eell-replaclng 
factor before enumeration of anti-sheep erythrocyte PFC 4 d  later (see Materials and Methods). 
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FIG. 2.  Inhibition of Ig secretion  in vivo. (A) Irradiated recipient mice (700 rad)  were injected 
with 10 p.g TNP-Ficoll and (I) 106 B cells, (II) no cells (sham injection), or (III)  106 B cells plus 10  ~ 
CI.Ly-I-2-NK-I+/I  1 (see Materials and Methods).  Anti-TNP PFC were determined 7 d later. (B) 
Irradiated recipient mice (700 rad) were injected with (I) 10  s T cells, (II) no cells (sham injection), 
or (III) l0  s T cells +  105 C1.Ly-I-2-NK-I+/11. Spleen cells were removed  7 d later, and 105 viable 
cells were  incubated with  10  e B  cells  plus sheep  erythrocytes  in vitro.  Anti-SRBC PFC were 
enumerated 4 d  later (see Materials and Methods).  (C)  Dose-response of inhibition of B cell Ig 
secretion in vivo by CI.Ly-I-2-NK-I+/11. Irradiated recipient mice (700 rad) were injected with 10 
p.g TNP Ficoll, 10nB cells, and increasing numbers of CI.Ly-I-2-NK-I+/11. Anti-TNP PFC were 
determined 7 d later. 
with TNP-FicolI, and  tested  for  anti-TNP  PFC  7  d  later  (Fig.  2 A). The  anti-TNP 
response  of mice  infused with  as  few  as  5  ×  10  a  NK-I+/ll  cells  (0.5%  of the  total 
nonirradiated cells in the host)  was  virtually eliminated.  Similar to  in vitro experi- 
ments, suppression was observed when NK-1+/11  represented as little as 0.1% of the 
total  lymphocytes  (Fig.  2C).  To  test  the  in  vivo  effect  of NK-I+/ll  cells  on  the 
development of T  helper function, irradiated mice were infused with  Ly-1  cells and 
SRBC for 5  d  alone, with graded numbers of NK cells. There was no inhibition of T 
helper activity by NK  cells tested  in vitro, as  described  in Materials  and  Methods, 
except  when  Ly-1  cells  were  incubated  with  very  large  numbers  of NKI+/ll  (1:1 
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Fro.  3.  Lysis and inhibition of Ig secretion in MHC-different target ceils. (A) CI.Ly-I-2-NK-I+/ 
11  cells were incubated with radiolabeled MBL-2 (C57B1/6 lymphoma), B10.D2N  LPS-activated 
B cells, or B10 LPS-activated B cells for 3.5 h, and lytic activity was determined from release of 
51Cr. (B) Lysis of radiolabeled B10.D2N or B10 LPS-activated B lymphocytes by cells from line 18, 
a B10 T cell growth factor-dependent CTL line stimulated for 3 min in vitro with B10.D2 cells. (C) 
Inhibition of Ig secretion  in syngeneic B6 spleen cells. Increasing numbers of CI.Ly-1-2-NK-1+/11 
were incubated with  106  B6  spleen cells  +  106  sheep erythrocytes in  vitro  (see  Materials and 
Methods). Anti-SRBC Ig secretion  was determined 4 d  later.  Control cultures containing spleen 
cells without SRBC yielded 20 PFC/culture, and spleen ceils in the absence of NK clone produced 
132 PFC/culture. (D) Inhibition of Ig secretion  in H-2-congenic B 10.D2N spleen cells. Spleen cells 
in the absence of NK clone produced 128 PFC/culture, whereas control cultures without antigen 
yielded 40 PFC/culture. 
CI.Ly-I-2-NK-I+/ l l  Lyses Activates B  Cells in a Non-H-2-restricted Fashion.  Because 
activated B lymphocytes express MHC determinants (11,  12) and these can play an 
important  role  in  T  cell  suppression  (13,  14), we  tested  whether  NK-I+/ll  cells 
recognized MHC-linked determinants as judged by lysis. In contrast to H-2-specific 
cytotoxic T  lymphocyte (CTL) lines, NK-I+/11 cells lysed B lymphocytes from mice 
congenic at the H-2 locus (Fig. 3A and B). NK-I+/11 cells lyse activated B lympho- 
cytes from all mouse strains tested with equal efficiency, including strains congenic at 
the GIX, H-2, Ly-1, Ly-2, and Thy-1 loci (not shown). 
Inhibition of B Cell Ig Secretion by Cl.Ly-1-2-NK-1+/11 Is Not Restricted to MHC-identical 
Target Cells.  To determine whether inhibition of B cell Ig secretion by NK-1+/11 
was restricted by MHC genes, NK-I+/I 1 cells were incubated with SRBC and spleen 
cells  from B6  or B10.D2N  mice.  Anti-SRBC  PFC  activity was  almost completely 
abolished in cell cultures containing as few as 10  a NK-1 ÷/11 cells (0.1% of total cells), 
regardless  of H-2  haplotype  (Fig.  3C  and  3 D).  Similarly, 83%  inhibition of the 
maximum PFC response of BALB/c spleen cells was noted in cultures containing 5 
×  10  a NK-I+/11 cells. Cultures of enriched B cells contained ~50% viable cells after 
incubation with or without NK-1+/11. 
Discussion 
NK cells display at least two patterns of lyric activity in mice (15).  One pattern 
includes lysis of virus-infected tumor targets such as the YAC-1,  RLd, MBL-2, or 
RBL-5 lymphomas by spleen cells.  A second often follows activation by substances 
such as Calmette-Guerin bacillus, interferon inducers, certain tumors, or other unde- 
fined factors, and is characterized by acquisition of lytic activity of additional tumors 
(e.g.,  EL4 lymphoma or  P815  mastocytoma)  (3,  15). These  latter  cells have been 
termed "activated" NK cells.  We previously described (3)  a  cloned cell line, C1.Ly- 
1-2-NK-I+/11, that mediates activated NK cell function. We found that this clone 
also lysed a variety of nonmalignant lymphoid cells, including B but not T  lympho- 662  NABEL  ET  AL.  BRIEF  DEFINITIVE  REPORT 
cytes.  We  therefore postulated  that  it  might  play  a  role  in  the  regulation  of Ig 
secretion. 
In this report, we show that CI.Ly-1-2-NK-1+/11 cells potently inhibit Ig secretion 
by B cells both in vitro and in vivo. The latter finding suggests that this mechanism 
may play a role in the regulation of normal antibody response. Indeed, Ly-1-2- spleen 
cells  contain  potent  Ly-l-2-5  ÷  cells  (L.  Glimcher,  L.  Boudreau,  and  H.  Cantor, 
manuscript in preparation)  that directly inhibit Ig secretion by B cells, as measured 
by a reverse PFC assay. 
Our data suggest that activated B cells rather than antigen-presenting cells are the 
cellular target for C1.Ly-I-2-NK-I+/11 because, in our hands, adherent cells are not 
required to support Ig secretion in cell cultures supplemented by the TRF preparations 
(in contrast  to supplementation by T  helper cells)  (data  not shown).  However, we 
cannot  exclude the  possibility  that  in  some  cases  macrophages  may  represent  an 
additional target cell. Although we occasionally observed that large numbers of NK- 
1+/11  cells  suppress  T  helper cells educated  in  vivo  (tested  by subsequent  helper 
activity measured in vitro), in most  instances, this is caused by residual NK-I+/11 
acting directly on B cells during the in vitro assay and can be eliminated by treating 
the educated cells with aNK-1.1 +  C'. 
To define the gene controlling the target structures on activated B cells, we tested 
a variety of LPS-activated B cells from inbred mice congenic at different loci. CI.Ly- 
1-2-NK-I+/11  lysed B cells from all strains tested, including strains that differed at 
the  MHC,  Lyt, Thy-1, and  GIX loci.  Because target  B  cells were often grown  in 
media supplemented with FCS, we considered the possibility that a serum constituent 
might be recognized on activated B cells. However, such recognition probably does 
not  account  for  target  cell  sensitivity  to  lysis  because  normal  mouse  mast  cells, 
thymocytes, and certain tumors that  are also grown in FCS-supplemented cultures 
are not susceptible to lysis.  Moreover, this cannot explain NK suppression of B cells 
in vivo because the adoptively transferred lymphocytes were never exposed to FCS. 
LPS-activated B lymphocytes express viral glycoproteins. The possibility that the 
target  molecules may cross-react with viral determinants similar to those found on 
tumor targets is consistent with our observation that the YAC-1  lymphoma inhibits 
lysis of activated B cell targets by CI.Ly-I-2-NK-1+/11 (data not shown). However, 
so far we have been unable to block lysis of B cells using anti-gp 70 antibody or other 
anti-viral antisera reagents. 
The observation that Ig secretion can be inhibited by C1.Ly-1-2-NK-1  +/11 suggests 
a novel mechanism for an immunoregulation circuit in which control of Ig secretion 
is mediated by direct recognition of a B cell surface structure, independent of antigen. 
This cell surface marker on activated B cells may be recognized by NK-like regulatory 
cells and serve to "mark" particular cells for death after activation by either T  cell 
products, certain viruses (16), or a given foreign antigen. In the latter case, this might 
result in deletion of B cell clones bearing Ig receptors specific for that antigen. The 
availability of continuously propagatable B cell lines should allow direct examination 
of this hypothesis and  further definition of B  cell surface molecules recognized by 
activated NK-like clones. 
Summary 
We previously described a cloned cell line that combines information for a unique 
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killer (NK) cells. In addition  to conventional cellular targets such as the YAC-1 and 
MBL-2  lymphomas, this  cloned  line also lysed lipopolysaccharide-activated  B  lym- 
phocytes. To determine whether some NK cells can inhibit  B cell function, we tested 
the ability of NK-like clones to suppress Ig secretion in vitro and in vivo. These cloned 
cells  suppressed  Ig secretion  when  they constituted  as  few  as 0.2%  of the  total  cell 
population and inhibition did not require identity at the H-2 locus. We suggest that 
some NK cells might recognize non-major histocompatibility complex gene products 
on activated  B  lymphocytes and  lyse these cells, and  this  might  represent  a  funda- 
mental cell-cell interaction that regulates antibody secretion by activated B cells. 
References 
1.  Nabei, G., J. S. Greenberger, M. A. Sakakeeney, and H. Cantor.  1981. Multiple biologic 
activities of a cloned inducer T cell population. Proc. Natl. Acad. Sci. U. S. A.  78.'1157. 
2.  Nabel,  G.,  S. J.  Galli,  A.  M.  Dvorak,  H.  F.  Dvorak, and  H.  Cantor.  1981.  Inducer T 
lymphocytes synthesize a  factor that stimulates  proliferation of cloned mast cells.  Nature 
(Lond.).  291:352. 
3.  Nabel, G., L. R. Bucalo, J. Allard, H. Wigzell, and H. Cantor.  1981. Multiple activities of 
a cloned cell line meditating natural killer  function.J. Exp. Med. 153:1582. 
4.  Shen,  F.  W.,  E.  A.  Boyse, and  H.  Cantor.  1975. Preparation  and  use  of Ly antisera. 
Immunogenetics. 2:591. 
5.  Nabel, G., M. Fresno, A. Chessman, and H. Cantor.  1981. Use of cloned populations of 
mouse lymphocytes to analyze cellular differentiation. Cell, 23:19. 
6.  Lionetti, F. J., S. M. Hunt,  R. J.  Mattaliano,  and C.  R. Valeri.  1978. In vitro studies of 
cryopreserved baboon granulocytes. Transfusion. 18:685. 
7.  Kiessling,  R.,  E.  Klein,  and  H.  Wigzell.  1975a.  "Natural"  killer  cells  in  the  mouse  I. 
Cytotoxic cells with specificity for mouse Moloney leukemia cells.  Specificity and distri- 
bution according to genotype. Eur. J. Immunol. 5:112. 
8.  Kiessling,  R., E. Klein, H. Pross, and H. Wigzell. 1975b. "Natural" killer cells in the mouse 
II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the 
killer cell. Eur. J. Immunol. 5:117. 
9.  Fresno, M., G. Nabel, L. Boudreau, H. Furthmayer, and H. Cantor.  1981. Antigen-specific 
T  lymphocyte clones.  I.  Characterization  of a  T  lymphocyte clone expressing  antigen- 
specific suppressive activity.J. Exp. Med. 153:1246. 
10.  Schimpl, A., and E. Wecker.  1972. Replacement of T  cell  function by a T  cell  product. 
Nature (Lond.).  237:15. 
11.  Sachs, D., and J. L. Cone. 1973. A mouse B-cell alloantigen determined by gene(s)  linked 
to the major histocompatibility complex. J. Exp. Med. 138:1289. 
12.  Unanue, E. R., M. E. Doff, C. S. David, and B. Benacerraf. 1974. The presence of I-region- 
associated antigens on B cells in molecules distinct from immunoglobulin and H-2K and 
H-2D, Proc. Natl. Acad. Sci. U. S. A. 71:5014. 
13.  Kapp, J.  A., C.  W.  Pierce, S.  Schlossman,  and  B.  Benacerraf.  1974.  Genetic control of 
immune responses in vitro. V. Stimulation of suppressor T  cells in nonresponder mice by 
the terpolymer L-glutamic acid6°-L-alanine~°-w-tyrosine. I° (GAT). J. Exp. Med. 140:648. 
14.  Sercarz, E.  E.,  R. L. Yowell,  D. Turkin, A. Miller,  B. A. Araneo, and L. Adorini.  1978. 
Different functional specificity repertoires for suppressor and helper T  cells. Immunol. Rev. 
39:108. 
15.  Minato, N., L. Reid, and B. Bloom.  1981. On the heterogeneity of murine natural  killer 
cells.J. Exp. Med. 154:750. 
16.  Klein, E., and G. Klein.  1981. Immunological control of EBV infected B cells. In Biochem- 
ical  and  Biological  Markers  of Neoplastic  Transformation  (Prakash  Chandra,  editor. 
Plenum Press, New York. 